Development and validation of a chemotherapy-induced taste alteration scale.
Taro Kano, Kiyoko Kanda
https://pubmed.ncbi.nlm.nih.gov/23448748/Actively Recruiting
Led by Wake Forest University Health Sciences · Updated on 2026-05-22
400
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to improve understanding and management of taste changes caused by chemotherapy in adult cancer patients. It evaluates whether adding a nurse-led, detailed taste alteration assessment and education helps patients detect and manage these taste changes better than usual care. The study includes a diverse group of cancer patients undergoing chemotherapy, focusing on taste alteration symptoms, patient actions, and dietary intake. Participants receive care based on their clinics assignment usual care or an intervention with nurse-led self-assessment and self-management of taste alterations. The intervention uses a validated taste assessment tool Chemotherapy-induced Taste Alterations Scale and patient education materials to help manage symptoms. Usual care includes standard chemotherapy education and a simple taste alteration severity question. Data collection occurs before chemotherapy starts, through the first four chemotherapy cycles, and continues for six months. Participants complete baseline assessments and patient education, report taste alteration symptoms during chemotherapy visits, and work with nurse coaches. The study tracks taste alteration severity, patient interventions, dietary intake, and body mass index over six months. Data collection and patient support continue throughout the chemotherapy cycles and follow-up period to assess the interventions impact on symptom management and nutrition.
CONDITIONS
Taste Alterations Study
M
Mary L Hook, PhD, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Wake Forest University Health Sciences
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Nurse-led TA Self-management | Usual Care |
|---|---|---|
| What it is | A structured, nurse-led behavioral program teaching patients to self-assess taste changes using the Chemotherapy-induced Taste Alterations Scale and choose evidence-based strategies for managing symptoms. | Routine oncology care for taste changes, without structured education or symptom-specific nurse-led self-management tools. |
| Role in the trial | Participants receive structured support and tools to monitor and address taste changes during chemotherapy. | Participants continue with the standard care their oncology team typically provides during chemotherapy. |
| Primary use or goal | To reduce the severity and impact of chemotherapy-induced taste alterations and encourage dietary intake maintenance through guided self-management. | Relief of taste alteration symptoms, but without systematic monitoring or tailored patient strategies. |
| How it is given or performed | Patients complete a validated taste alteration scale, receive nurse-guided education on symptom management, and select interventions using a dedicated education sheet during chemotherapy. | Symptom management and supportive guidance are provided at the usual discretion of oncology staff, without protocol-specific tools or materials for taste changes. |
| Evidence status | Preliminary randomized trials suggest nurse-led self-assessment and education interventions may help reduce taste change severity and improve dietary intake in patients receiving chemotherapy, though high-certainty evidence is limited. | Usual care provides inconsistent or ad hoc symptom management; no high-quality evidence supports systematic reduction of taste alterations without dedicated interventions. |
| Important limitations | The intervention may require extra time and effort, relies on patient engagement with nurses and self-monitoring tools, and results for populations outside common cancer types or non-English speakers remain unknown. | Usual care may overlook taste changes, lacks structured assessment and management, and may result in unmet patient needs or variable dietary outcomes. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - During the first 4 chemotherapy cycles over approximately 6 months
Participants receive chemotherapy and either usual care or a nurse-led intervention involving taste alteration self-assessment and self-management strategies to help manage taste alterations during chemotherapy.
Visits aligned with chemotherapy cycles, approximately 4 cycles over 6 months
Duration - Up to 6 months following treatment initiation
Participants are monitored for taste alteration severity, dietary intake, and body mass index through the completion of the study.
Ongoing assessments during treatment visits up to 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Taro Kano, Kiyoko Kanda
https://pubmed.ncbi.nlm.nih.gov/23448748/Linda A Barlow
https://pubmed.ncbi.nlm.nih.gov/34850604/Taeko Kinjo, Kiyoko Kanda, Keiko Fujimoto
https://pubmed.ncbi.nlm.nih.gov/33940487/Tania Buttiron Webber, Irene Maria Briata, Andrea DeCensi...
https://pubmed.ncbi.nlm.nih.gov/36768861/Sumanth Kumbargere Nagraj, Renjith P George, Naresh Shetty...
https://pubmed.ncbi.nlm.nih.gov/29260510/Adeline Braud, Yves Boucher
https://pubmed.ncbi.nlm.nih.gov/32385655/Paule V Joseph, Alissa Nolden, Kord M Kober...
https://pubmed.ncbi.nlm.nih.gov/33259906/Julia von Grundherr, Barbara Koch, Donata Grimm...
https://pubmed.ncbi.nlm.nih.gov/31191011/Sanae Asano, Hiroyuki Sawatari, Hideko Mentani...
https://pubmed.ncbi.nlm.nih.gov/32441675/Wake Forest University Health Sciences
Lead Sponsor